Caspian Journal of Internal Medicine
Babol University of Medical Sciences
Mon, Dec 23, 2024
[Archive]
Volume 13, Issue 2 (Spring 2022)
Caspian J Intern Med 2022, 13(2): 349-355 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Abbaszade Marzbali N, Zabihi E, Magne N, Vallard A, Moslemi M, Moslemi D. Recover burn ointment for managing acute radiodermatitis in patients with breast cancer: A double blind randomized controlled trial. Caspian J Intern Med 2022; 13 (2) :349-355
URL: http://caspjim.com/article-1-2568-en.html
URL: http://caspjim.com/article-1-2568-en.html
Nargeuss Abbaszade Marzbali 
, Ebrahim Zabihi , Nicolas Magne , Alexis Vallard , Mohammad Moslemi , Dariush Moslemi *
, Ebrahim Zabihi , Nicolas Magne , Alexis Vallard , Mohammad Moslemi , Dariush Moslemi *
Babol University of Medical Sciences , moslemi_d@yahoo.com
Abstract: (3002 Views)
Background: Radiodermatitis is the most common complication of radiotherapy. There is no gold standard for managing the radiodermatitis. This study aimed to evaluate the effect of topical Recove® burn ointment; basically compounded of sesame oil, camphor, and zinc oxide; in preventing acute radiodermatitis.
Methods: This double blind RCT (IRCT No.: 201204047136N2) was performed on 71 patients that referred for radiotherapy after mastectomy to Shahid Rajaee Hospital (Babolsar-Iran) during 2013-2017. Patients were allocated into 2 groups; 34 in control group and 37 in Recove® group. Patients applied the ointment 2 times a day, before every radiation therapy session for 5 weeks. The radiation oncologist assessed the severity of dermatitis weekly for 5 weeks and graded it from 0 to 4 according to the RTOG criteria.
Results:Baseline characteristics including age, and BMI had no significant difference between groups. The Recover group patients experienced significantly less severe dermatitis compared to the controls (p<0.001). None of the patients in Recove® group encountered more than grade 2 of RTOG criteria, however, in the control group, 4 (12.9%)patients experienced grade 3 of RTOG and 3 (9.7%)patients developed grade 4 of RTOG at the end of the 5th week.
Conclusion: Our results indicate that Recove® ointment significantly reduces the severity of acute radiodermatitis.
Methods: This double blind RCT (IRCT No.: 201204047136N2) was performed on 71 patients that referred for radiotherapy after mastectomy to Shahid Rajaee Hospital (Babolsar-Iran) during 2013-2017. Patients were allocated into 2 groups; 34 in control group and 37 in Recove® group. Patients applied the ointment 2 times a day, before every radiation therapy session for 5 weeks. The radiation oncologist assessed the severity of dermatitis weekly for 5 weeks and graded it from 0 to 4 according to the RTOG criteria.
Results:Baseline characteristics including age, and BMI had no significant difference between groups. The Recover group patients experienced significantly less severe dermatitis compared to the controls (p<0.001). None of the patients in Recove® group encountered more than grade 2 of RTOG criteria, however, in the control group, 4 (12.9%)patients experienced grade 3 of RTOG and 3 (9.7%)patients developed grade 4 of RTOG at the end of the 5th week.
Conclusion: Our results indicate that Recove® ointment significantly reduces the severity of acute radiodermatitis.
Keywords: breast cancer, radiotherapy, radiodermatitis, Recove ointment, radiation therapy oncology group.
Type of Study: Original Article |
Subject:
Oncology
Received: 2020/10/29 | Accepted: 2021/08/22 | Published: 2022/02/21
Received: 2020/10/29 | Accepted: 2021/08/22 | Published: 2022/02/21
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
